Using metabolomic profiling to screen for endometrial cancer
Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer
This study is testing a new way to use blood samples to see if certain markers can help identify endometrial cancer in women compared to other types of growths and cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3100 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | Female |
| Sponsor | National Cancer Institute, Naples Academic / other |
| Locations | 1 site (Naples) |
| Trial ID | NCT06893861 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a metabolomic signature for screening endometrial carcinoma by comparing it against benign endometrial neoplasms and other cancer types. It follows a case-control design, recruiting patients from the IRCCS G. Pascale and Diagnostica Medica for data collection and biological sample analysis. The study aims to assess the discriminative ability of the metabolomic signature through a combination of bioanalytical and bioinformatic methods. Participants will provide blood samples for metabolomic profiling to identify potential diagnostic markers.
Who should consider this trial
Good fit: Ideal candidates are post-menopausal women aged 50 to 80 who are willing to participate in the study.
Not a fit: Patients who have undergone a hysterectomy, are on hormone replacement therapy, or are receiving immunosuppressive therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate screening for endometrial cancer, improving patient outcomes.
How similar studies have performed: While the use of metabolomic profiling in cancer screening is an emerging field, this specific approach has not been widely tested, making it a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Female sex 2. Age between 50 and 80 years 3. Willingness to participate in the study and signing of the informed consent 4. Clinical condition of post-menopause Exclusion Criteria: 1. Previous hysterectomy 2. Hormone replacement therapy 3. Immunosuppressive therapy
Where this trial is running
Naples
- Istituto Nazionale Tumori | "Fondazione Pascale" — Naples, Italy (Recruiting)
Study contacts
- Principal investigator: Antonella De Luca — IRCCS I.N.T. "G. Pascale"
- Study coordinator: Antonella De Luca
- Email: a.deluca@istitutotumori.na.it
- Phone: 08117770603
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.